Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Amazingly….
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(93)
•••
Comment by lovingoldon Feb 20, 2022 6:00pm
84 Views
Post# 34446782

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Amazingly….

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Amazingly….I'm well aware of that Finallytherock.
Someone has to pay for the report ... always.
Find me one thing in the Zachs analyst report that is not factual.
...
...
...
I'm waiting ...
...
...
...

Again the world asks "why do you care about this company/stock if you've done your DD and believe there is nothing going on?".
Geez, perhaps if I spoon fed you that question you might start to understand.
You must believe there is something going on or why else would you keep asking to be disproven.
It's not the job of anyone on this board to convince you one way or the other.
You've stated your case now give it a rest lest readers think even less of you with your continual whining.
I can't even imagine the insanity level of a person that devotes so much time incessently asking for others to convince them about a stock they have no shares in and will never buy no matter what evidence is presented. Seriously, you should seek professional help.

I'm officially done with you and won't see you at the Bioasis celebration party - invites only go to those long the stock :)



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities